INOVIO to Present at Upcoming Scientific Conferences
INOVIO (NASDAQ:INO), a biotechnology company developing DNA medicines, announced its participation in four upcoming scientific conferences. These include:
1. AACR Special Conference in Boston, MA (Oct 19, 2024): Dr. Matthew Morrow will present a poster on INO-3107's impact on reducing surgical interventions for Recurrent Respiratory Papillomatosis (RRP).
2. ISV Congress 2024 in Seoul, Korea (Oct 22, 2024): Dr. Michael Sumner will give an oral presentation and poster on the clinical assessment of INO-3107 in adult RRP patients.
3. Fall Voice in Phoenix, AZ (Oct 25-26, 2024): Dr. Jeffrey Skolnik will present a poster on the clinical assessment of INO-3107 in adult RRP patients.
4. World Vaccine Congress Europe in Barcelona, Spain (Oct 28, 2024): Dr. Dave Liebowitz will give a presentation and participate in a panel discussion on platform technologies.
Abstracts from these conferences will be available on INOVIO's website after each presentation.
INOVIO (NASDAQ:INO), una azienda biotecnologica che sviluppa medicinali a base di DNA, ha annunciato la sua partecipazione a quattro prossime conferenze scientifiche. Queste includono:
1. Conferenza Speciale AACR a Boston, MA (19 ottobre 2024): Il Dr. Matthew Morrow presenterà un poster sull'impatto di INO-3107 nella riduzione degli interventi chirurgici per la Papillomatosi Respiratoria Ricorrente (RRP).
2. Congresso ISV 2024 a Seoul, Corea (22 ottobre 2024): Il Dr. Michael Sumner terrà una presentazione orale e presenterà un poster sulla valutazione clinica di INO-3107 nei pazienti adulti con RRP.
3. Fall Voice a Phoenix, AZ (25-26 ottobre 2024): Il Dr. Jeffrey Skolnik presenterà un poster sulla valutazione clinica di INO-3107 nei pazienti adulti con RRP.
4. World Vaccine Congress Europe a Barcellona, Spagna (28 ottobre 2024): Il Dr. Dave Liebowitz terrà una presentazione e parteciperà a una discussione di panel sulle tecnologie di piattaforma.
Gli abstract di queste conferenze saranno disponibili sul sito web di INOVIO dopo ogni presentazione.
INOVIO (NASDAQ:INO), una empresa biotecnológica que desarrolla medicamentos a base de ADN, anunció su participación en cuatro próximas conferencias científicas. Estas incluyen:
1. Conferencia Especial AACR en Boston, MA (19 de octubre de 2024): El Dr. Matthew Morrow presentará un póster sobre el impacto de INO-3107 en la reducción de intervenciones quirúrgicas por Papilomatosis Respiratoria Recurrente (RRP).
2. Congreso ISV 2024 en Seúl, Corea (22 de octubre de 2024): El Dr. Michael Sumner dará una presentación oral y presentará un póster sobre la evaluación clínica de INO-3107 en pacientes adultos con RRP.
3. Fall Voice en Phoenix, AZ (25-26 de octubre de 2024): El Dr. Jeffrey Skolnik presentará un póster sobre la evaluación clínica de INO-3107 en pacientes adultos con RRP.
4. Congreso Mundial de Vacunas Europa en Barcelona, España (28 de octubre de 2024): El Dr. Dave Liebowitz dará una presentación y participará en una discusión de panel sobre tecnologías de plataforma.
Los resúmenes de estas conferencias estarán disponibles en el sitio web de INOVIO después de cada presentación.
INOVIO (NASDAQ:INO), DNA 의약품을 개발하는 생명공학 회사가 향후 진행될 네 개의 과학 회의에 참여할 것이라고 발표했습니다. 다음과 같은 일정이 포함됩니다:
1. AACR 특별 회의 미국 매사추세츠주 보스턴 (2024년 10월 19일): 매튜 모로우 박사가 INO-3107이 재발성 호흡기 유두종증(RRP)의 외과적 개입을 줄이는 데 미치는 영향에 대한 포스터를 발표합니다.
2. ISV Congress 2024 한국 서울 (2024년 10월 22일): 마이클 섬너 박사가 성인 RRP 환자에서 INO-3107의 임상 평가에 대한 구술 발표 및 포스터를 제공합니다.
3. Fall Voice 미국 애리조나주 피닉스 (2024년 10월 25-26일): 제프리 스콜닉 박사가 성인 RRP 환자에서 INO-3107의 임상 평가에 대한 포스터를 발표합니다.
4. World Vaccine Congress Europe 스페인 바르셀로나 (2024년 10월 28일): 데이브 리보위츠 박사가 발표를 하고 플랫폼 기술에 관한 패널 토론에 참여합니다.
이 회의의 초록은 각 발표 후 INOVIO의 웹사이트에서 확인할 수 있습니다.
INOVIO (NASDAQ:INO), une entreprise biotechnologique développant des médicaments à base d'ADN, a annoncé sa participation à quatre prochaines conférences scientifiques. Celles-ci incluent :
1. Conférence Spéciale AACR à Boston, MA (19 octobre 2024) : Dr. Matthew Morrow présentera une affiche sur l'impact de INO-3107 dans la réduction des interventions chirurgicales pour la Papillomatose Respiratoire Récurrente (RRP).
2. Congrès ISV 2024 à Séoul, Corée (22 octobre 2024) : Dr. Michael Sumner fera une présentation orale et présentera une affiche sur l’évaluation clinique de INO-3107 chez les patients adultes atteints de RRP.
3. Fall Voice à Phoenix, AZ (25-26 octobre 2024) : Dr. Jeffrey Skolnik présentera une affiche sur l’évaluation clinique de INO-3107 chez les patients adultes atteints de RRP.
4. Congrès Mondial des Vaccins Europe à Barcelone, Espagne (28 octobre 2024) : Dr. Dave Liebowitz fera une présentation et participera à un débat sur les technologies de plateforme.
Les résumés de ces conférences seront disponibles sur le site Web d'INOVIO après chaque présentation.
INOVIO (NASDAQ:INO), ein biotechnologisches Unternehmen, das DNA-Medikamente entwickelt, gab seine Teilnahme an vier bevorstehenden wissenschaftlichen Konferenzen bekannt. Diese umfassen:
1. AACR Spezialkonferenz in Boston, MA (19. Oktober 2024): Dr. Matthew Morrow wird ein Poster über die Auswirkungen von INO-3107 auf die Reduzierung chirurgischer Eingriffe bei rekurrierender respiratorischer Papillomatose (RRP) präsentieren.
2. ISV Kongress 2024 in Seoul, Korea (22. Oktober 2024): Dr. Michael Sumner wird eine mündliche Präsentation und ein Poster zur klinischen Bewertung von INO-3107 bei erwachsenen RRP-Patienten halten.
3. Fall Voice in Phoenix, AZ (25.-26. Oktober 2024): Dr. Jeffrey Skolnik wird ein Poster zur klinischen Bewertung von INO-3107 bei erwachsenen RRP-Patienten präsentieren.
4. World Vaccine Congress Europe in Barcelona, Spanien (28. Oktober 2024): Dr. Dave Liebowitz wird eine Präsentation halten und an einer Podiumsdiskussion über Plattformtechnologien teilnehmen.
Abstracts von diesen Konferenzen werden nach jeder Präsentation auf der Website von INOVIO verfügbar sein.
- None.
- None.
AACR Special Conference in Cancer Research: Tumor Immunology and Immunotherapy
Poster by Dr. Matthew Morrow, VP of Translational Sciences at INOVIO
Abstract Title: Reduction in Surgical Interventions for the Treatment of Recurrent Respiratory Papillomatosis by INO-3107 is Associated with Enriched Macrophage, Dendritic cell and T cell Signatures in Patient Airways
Date and Time: October 19, 2024, 6:00 - 8:15pm ET
Location:
ISV Congress 2024
Oral presentation and poster by Dr. Michael Sumner, Chief Medical Officer at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 22, 2024, 4:20pm KST
Location:
Fall Voice
Poster by Dr. Jeffrey Skolnik, SVP of Clinical Development at INOVIO
Abstract Title: Clinical Assessment of Adjuvant Immunotherapy, INO-3107, in Adult Patients with Recurrent Respiratory Papillomatosis (RRP)
Date and Time: October 25 – October 26, 2024
Location:
World Vaccine Congress Europe
Presentation and panel discussion by Dr. Dave Liebowitz, SVP Early-Stage Clinical Development at INOVIO
Track: Pre-Congress Workshop on Platform Technologies
Date and Time: October 28, 2024, 10:00am CET
Location:
Abstracts from these conferences will be made available on INOVIO's website following each presentation.
About INOVIO
INOVIO is a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. INOVIO's technology optimizes the design and delivery of innovative DNA medicines that teach the body to manufacture its own disease-fighting tools. For more information, visit www.inovio.com.
Contacts
Media: Jennie Willson (267) 429-8567 jennie.willson@inovio.com
Investors: Thomas Hong (267) 440-4298 thomas.hong@inovio.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/inovio-to-present-at-upcoming-scientific-conferences-302263723.html
SOURCE INOVIO Pharmaceuticals, Inc.